Journal
BRITISH JOURNAL OF CANCER
Volume 122, Issue 3, Pages 293-294Publisher
SPRINGERNATURE
DOI: 10.1038/s41416-019-0645-9
Keywords
-
Categories
Ask authors/readers for more resources
Pancreatic cancers occurring in carriers of a pathogenic germline alteration in BRCA1/2 (gBRCA1/2) are assumed to demonstrate homologous recombination repair deficiency (HRD), associated with sensitivity to platinum-based chemotherapy and synthetic lethality with PARP inhibitors (PARPi). However, primary and secondary resistance to these agents occurs even in this highly selected population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available